Abstract
Patients with acute lymphoblastic leukemia (ALL) or relapsed/refractory (r/r) large B-cell lymphoma (LBCL) often progress rapidly, and current manufacture process of chimeric antigen receptor (CAR) T cells takes too long and resulting products are less optimal for in vivo expansion and function. The “DASH CAR-T” manufacturing process we developed enabled production of CAR-T cells of naïve phenotypes within 48 hours. We examined the efficacy of DASH CAR-T cells in a murine model and laid the foundation for novel clinical trials for patients with ALL or r/r B-ALL.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
